Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Moffitt Cancer Center
Deal Size : Undisclosed
Deal Type : Collaboration
RyboDyn Expands Strategic Cancer Immunotherapy Collaboration with Moffitt Cancer Center
Details : The collaboration aims to accelerate the development of immunotherapies targeting novel, cancer-specific proteins identified through RyboDyn's sequencing and AI-driven target discovery platform.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
May 15, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Moffitt Cancer Center
Deal Size : Undisclosed
Deal Type : Collaboration